Shear-thinning biomaterial-based minimally invasive strategy for delivery of targeted immunotherapy

By | August 2, 2022
Researchers at the Terasaki Institute for Biomedical Innovation (TIBI) have developed and optimized a minimally invasive method for more targeted, efficient, and sustained delivery of immunotherapeutic treatments for cancer.